Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
BioPharmaceutical

Esprit To Market Estrogen Therapy Estrasorb In 2006

This article was originally published in The Pink Sheet Daily

  • News

Executive Summary

The company gains rights to Novavax' topical estrogen therapy Estrasorb after the failure of Novavax' copromotion deal with King.

You may also be interested in...



Novavax CEO Rahul Singhvi – An Interview With “The Pink Sheet” DAILY, Part 2 of 3

Novavax execs describe the firm's Virus Like Particle technology and how disposable, egg-less virus manufacturing is changing the industry.

Novavax CEO Rahul Singhvi – An Interview With “The Pink Sheet” DAILY, Part 2 of 3

Novavax execs describe the firm's Virus Like Particle technology and how disposable, egg-less virus manufacturing is changing the industry.

Esprit Pharma Grabs Prosed EC Through Metagen Pharmaceuticals Buy

Esprit plans to promote Prosed EC with other overactive bladder treatments Proquin XR and Sanctura.

Table

View full table

Topics

Tags:
BioPharmaceutical
Latest Headlines

Pink Sheet Podcast: Leqembi Spending, Woodcock’s Next Act, Pneumococcal Vaccine Development

EU Consults On What Constitutes Personal & Commercially Confidential Data In Marketing Applications

Industry & Regulators To Align Advice on COVID-19 Vaccine Updates

Lack Of Industry Involvement In EU HTA Scoping Process Exacerbates ‘Unworkable’ Timelines

See All
UsernamePublicRestriction

Register

PS061115

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By